Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101)
To evaluate the safety and tolerability of sotorasib administered in investigational regimens in adult participants with KRAS p.G12C mutant advanced solid tumors.
Advanced Solid Tumors|Kirsten Rat Sarcoma (KRAS) pG12C Mutation
DRUG: Sotorasib|DRUG: Trametinib|DRUG: RMC-4630|DRUG: Afatinib|DRUG: Pembrolizumab|DRUG: Panitumumab|DRUG: Carboplatin, pemetrexed, docetaxel, paclitaxel|DRUG: Atezolizumab|DRUG: Palbociclib|DRUG: MVASIÂ® (bevacizumab-awwb)|DRUG: TNO155|DRUG: IV Chemotherapy (Regimen 1)|DRUG: IV Chemotherapy (Regimen 2)|DRUG: BI 1701963|DRUG: AMG 404|DRUG: Everolimus
Number of Participants with Dose Limiting Toxicities (DLTs), 12 Months|Number of Participants with Treatment-emergent Adverse Events (TEAEs), 12 Months|Number of Participants with Treatment-related Adverse Events, 12 Months|Number of Participants with Clinically Significant Changes in Vital Signs, 12 Months|Number of Participants with Clinically Significant Changes in ECG Measurements, 12 Months|Number of Participants with Clinically Significant Changes in Laboratory Test Values, 12 Months
Maximum Plasma Concentration (Cmax), 12 Months|Time to Maximum Plasma Concentration (Tmax), 12 Months|Area Under the Plasma Concentration-time Curve (AUC), 12 Months|Objective Response Rate, 12 Months|Disease Control Rate, 12 Months|Duration of Response, 12 Months|Progression-free Survival, 12 Months|Duration of Stable Disease, 12 Months|Time to Response, 12 Months|Overall Survival, 12 Months|Sotorasib + EGFR Inhibitor +/- Chemotherapeutic Regimen Only: Quantification of Plasma Levels, 12 Months|Sotorasib Monotherapy Only: Intracranial Objective Response Rate, Intracranial objective response rate assessed per Response Assessment in Neuro-oncology Brain Metastases (RANO-BM)., 12 Months|Sotorasib Monotherapy Only: Intracranial Disease Control Rate, Intracranial disease control rate assessed per RANO-BM., 12 Months|Sotorasib Monotherapy Only: Intracranial Duration of Response, Intracranial duration of response assessed per RANO-BM., 12 Months|Sotorasib Monotherapy Only: Time to Intracranial Radiation Therapy, 12 Months|Sotorasib Monotherapy Only: Intracranial Progression-free Survival (PFS), Intracranial PFS assessed per RANO-BM., 12 Months|Sotorasib Monotherapy Only: Non-intracranial Progression-free Survival (PFS), Non-intracranial PFS assessed per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1., 12 Months|Sotorasib Monotherapy Only: Overall Progression-free Survival (PFS), Overall PFS assessed per RECIST 1.1 and RANO-BM., 12 Months|Sotorasib + TNO155 Only: Best Overall Response, 12 Months|Sotorasib + Afatinib + Loperamide Only: Number of Participants with Dose Limiting Toxicities (DLTs), 12 Months|Sotorasib + Afatinib + Loperamide Only: Number of Participants with Treatment-emergent Adverse Events (TEAEs), 12 Months|Sotorasib + Afatinib + Loperamide Only: Number of Participants with Treatment-related Adverse Events, 12 Months|Sotorasib + Afatinib + Loperamide Only: Number of Participants with Clinically Significant Changes in Vital Signs, 12 Months|Sotorasib + Afatinib + Loperamide Only: Number of Participants with Clinically Significant Changes in ECG Measurements, 12 Months|Sotorasib + Afatinib + Loperamide Only: Number of Participants with Clinically Significant Changes in Laboratory Test Values, 12 Months
To evaluate the safety and tolerability of sotorasib administered in investigational regimens in adult participants with KRAS p.G12C mutant advanced solid tumors.